Methods by which patients can artificially produce raised peak flow measurements have been described. We recently observed a patient manipulating the peak flow meter in a way that had not been described before. A study was therefore undertaken to determine if this technique could repeatedly produce clinically significant changes in peak flow readings. Fifteen adults, using a mini-Wright peak flow meter, made five measurements using the correct technique followed by five manipulated measurements under observation. Significant increases in peak flow measurements were observed in 14 of the 15 subjects. The mean increase in peak flow rate using the incorrect technique was 56% (range -4% to 86%). Clinicians should be aware that patients might employ this technique to manipulate measurements which could have consequences for management. (Thorax 2001;56:500-501) Keywords: peak flow measurements; technique; false results Peak flow measurement is used in asthma management. 1 We are aware that peak flow measurements can be artificially increased by spitting or coughing.
Peak flow measurement is used in asthma management. 1 We are aware that peak flow measurements can be artificially increased by spitting or coughing. 2 3 We recently observed a method of manipulating peak flow measurement which has not been previously described.
Case report
A 13 year old asthmatic boy was seen as an outpatient. He was prone to recurrent acute attacks of asthma and had four hospital admissions in the previous 3 months. The patient was asked to perform a peak flow measurement. During the manoeuvre his movements appeared slightly awkward and, when asked to explain, he admitted that he had discovered that, if he retarded the movement of the peak flow indicator with his index finger at the beginning of the manoeuvre for a fraction of a second after starting to exhale (fig 1) , he could increase the reading. He also explained that, if he moved vigorously during the procedure, it appeared that he was giving maximum eVort to performing the measurement and 2  500  634  27  520  660  27  3  613  710  16  625  800*  28  4  516  712  38  590  800*  36  5  490  512  4  510  540  6  6  526  730  39  530  800*  51  7  628  760  21  640  800*  25  8  548  537  −2  575  550  −4  9  414  688  66  420  780  86  10  439  602  37  450  800*  78  11  402  432  7  410  480  17  12  522  650  24  540  800*  48  13  468  616  32  480  750  56  14  432  594  37  440  800*  82  15  294  408  39  350  440  26 *These subjects produced several peak flow measurements beyond 800 (top of the scale) which were recorded as 800 for the purpose of calculating the mean recording and relative increase. this made it diYcult for the doctor to detect what he was doing with his finger. A study was therefore undertaken to determine whether this technique could repeatedly produce clinically significant changes in peak flow readings.
Methods
Fifteen adults, one of whom had asthma, were asked to make five peak flow measurements in the standard way followed by a further five peak flow measurements by retarding the movement of the peak flow indicator as described in the case report, after an initial practice. All measurements were carried out using a mini-Wright peak flow meter.
Results
The results are shown in table 1. Both the mean and the best of five readings for the two techniques were recorded. It can be seen that altering the technique of peak flow measurement (as described in the case study) produced significant increases in peak flow rate in 14 of the 15 subjects. Using the mean of the five attempts, a mean increase of 28% (range -2% to 66%) was achieved. When the highest of the five attempts was taken as representative, the mean increase was 56% (range -4% to 85%).
Discussion
Peak flow recording is important in asthma management 1 and these measurements are used to inform decisions about the need for referral to hospital, admission, and timing of discharge. Patients dislike being in hospital and may be tempted to manipulate peak flow measurements in order to give falsely raised readings that could influence their management. For example, patients may have a true peak flow <50% of their personal best but, by falsely increasing the peak flow measurement by 28%, management could be quite diVerent. Clinicians need to be aware of this and of other manoeuvres that lead to falsely raised readings. We would emphasise that it is possible to interfere with the movement of the peak flow indicator with subtlety and this would not be readily noticed unless the clinician is watching closely. Asking patients to "cradle" the peak flow meter with a hand underneath the device is likely to prevent this problem. 
LETTERS TO THE EDITOR

CFC transition
Dr Everard wrote such a wide ranging polemic against inhaled therapy that it is difficult to know where to start. While the article contains a good deal of sense, it also contains a number of inaccuracies and misperceptions. I think the record needs to be put straight. Firstly, Dr Everard says that inhaled insulin will be in use in 2001. However, as far as I am aware, no application for delivery of insulin as an aerosol has yet been submitted to the FDA. New devices for the delivery of insulin are under trial, but the earliest they are likely to get to the market is 2002. They are likely to be relatively complex devices costing perhaps 100 times more than the current price for a salbutamol metered dose inhaler (MDI).
Secondly, Dr Everard berates the pharmaceutical industry for its eVorts in moving away from chlorofluorocarbon (CFC) MDIs. In 1996, when the Montreal protocol came into force, there was a real risk that MDIs for use in asthma/COPD would no longer be available. The industry started 10 years ago to try to reformulate MDIs but the technical challenge has been enormous and complicated by intellectual property issues. Only now, more than a decade later, are a suYcient number of CFC free MDIs coming to the market so that the transition can be completed over the next 2-4 years. This has cost a huge amount of money. But where is the evidence that they prevented new chemical entities for asthma coming to the market? If such clinically eYcacious compounds were available, then I am certain that they would have been commercially exploited.
Thirdly, Dr Everard is correct in stating that the MDI in some ways is a less than ideal inhalation device. The new hydrofluorocarbon (HFC) beclomethasone product (Qvar, 3M Pharmaceuticals) has a much smaller particle size, not by design but by necessity. This results in something like 5-6 times more drug being deposited peripherally in the lung but only twice the therapeutic eVect compared with the MDI it replaces. This product has given a big "wake up call" to the industry and we should all be asking which particle size really is ideal, particularly for inhaled steroids. Is it diVerent, for example, for beclomethasone versus budesonide versus fluticasone? I am also unaware of any data that monodispersed aerosols are more eYcacious or safer than aerosols with a more broad range of particle size.
Fourthly, Dr Everard mixes in with the discussion of technology a rather paternalistic view of patient compliance. If only patients would do as they are told and take their medication all would be well. Does anyone ever complete a course of antibiotics? We badly need more information about why patients do not adhere to medication regimes and what information they need about their disease and the treatments used. But isn't this true for all therapies? Dose counters to improve compliance might be valuable for MDIs-but where is the evidence that they are cost eVective, or even that doctors or patients want them?
I am firmly convinced that the MDI, along with the dry powder inhaler (DPI), is here to stay. They are remarkably cheap, instantly eVective as bronchodilators, and have an excellent therapeutic ratio for inhaled steroids for most asthmatics. Many patients can use up to 2000 doses per year without their inhaler letting them down, and perhaps it is not surprising that they become reliant on them. Certainly they can be improved upon. Novel devices using aqueous and hydrocarbon propellants are on their way. But if Dr Everard sees any viable and cost eVective alternatives, then let us hear about them. Mark Everard's superb leading article 1 railing against the numerous inadequacies of inhaled therapy delivered by pMDIs is to be applauded, but ultimately is an unsatisfying tract since it does not point to any solutions applicable in the here and now. The single most important advance in the treatment of asthma at the beginning of the 21st century would be to wean ourselves-and by that I mean the UK since the process is already well advanced in continental Europe-from the use of these archaic impediments to treatment. Everard is right that the regulatory authorities bear a heavy burden of guilt by requiring devices which result in greater lung deposition to undergo much more extensive, and therefore costly, investigation than "me too" devices mimicking the appalling performance of pMDIs. I have witnessed the "detuning" of novel inhalers that he refers to in order to limbo under this bureaucratic hurdle. Removing the equivalence straight jacket for inhaler devices would, at a stroke, allow currently available devices to be used to their maximum and not minimum potential.
Why are the British so hooked on the inadequate and obsolete pMDI? It is simply that Thorax 2001;56:501-504 the currently available alternative-dry powder inhalers-are perceived to be more costly. This view has been led by the Department of Health who have calculated that swapping device for device would cost them a great deal of money. This, however, is the accountancy of the madhouse. Because dry powder inhalers are more eYcient at drug delivery, the Fairy Liquid argument holds and the cost of treatment rather than the cost of the device should be used in their calculations. Of course, such back of the cigarette packet arithmetic should be banished by the new god of evidence based medicine. So what is the evidence on cost? Howarth et al have performed an audit of patients who have been transferred to dry powder inhalers because they were unable to use pMDIs. 2 The cost of treatment with inhaled steroids was actually lower with dry powder inhalers. The only randomised controlled trial using the overpriced Turbohaler came to a similar conclusion. 3 Thus, what little evidence that is available suggests that prescribing even premium priced dry powder inhalers for the delivery of inhaled steroids may be cheaper than using pMDIs. There can be no argument that there is a cost impediment with the more recent introduction of generic dry powder inhalers which are competitive even on a device for device basis.
Everard rightly points out that the issues of compliance, competence, and contrivance are closely interlinked. What is rarely taken into account in the equation is the patient preference. We have recently analysed the results of three separate studies comparing the market leading pMDI with the Clickhaler in terms of patient preference in 118 paediatric and 221 adult patients. 4 Significantly more (63%) preferred the dry powder inhaler to the pMDI (28%) (p<0.01). The dry powder inhaler was also significantly better on other criteria such as ease of use and ease of preparation. Similar results have been obtained in a meta-analysis of comparative studies of 802 patients using the dry powder device Easyhaler. 5 If patient preference is a surrogate for compliance, then two of Everard's three Cs can be dealt with today by transferring patients not optimally managed on pMDIs to dry powder devices.
The third C-contrivance-will be tackled shortly with the advent of new chip technologies already available in nebulised devices such as the Halolite Adaptive Aerosol Delivery (AAD) system. In Hull, Kastelik and Aziz have recorded patient compliance in 23 subjects using the AAD system and have unsurprisingly found that 20% of patients were poor compliers (<70% of doses). We have been unable to detect this lack of compliance during a formal structured interview or on diary record cards. In future the identification of such problems with smaller devices attached to inhalers will not only be of great medical benefit but also, I suspect, will be led by cost. Vast sums of money are wasted in health care by poor adherence to treatment. Woodcock appears to have misunderstood the purpose of the article when he characterises it as "polemic against inhaled therapy". The article was written precisely because I do recognise the importance of inhaled therapy and, in particular, the importance of inhaled corticosteroids for the treatment of asthma. Since aerosol therapy is so important, it should be clear that patients deserve to be provided with devices that deliver the drugs reliably and safely to the lungs. More than a decade ago pharmaceutical companies understandably decided to develop CFC replacement pMDIs. This was not because this was the best solution for patients but because at the time it appeared to be the quickest and cheapest solution. Much to their dismay, they found that this has proved to be a very expensive and long winded exercise. It is, however, important to recognise that the major error in judgement at that time was not that they underestimated the diYculties involved, but the failure to recognise the limitations of the pMDI as a delivery system for drugs other than short acting agonists. The pMDI was a brilliant solution for a particular problem but does not eVectively meet the needs of drugs such as inhaled corticosteroids. The challenges for device developers are, firstly, that they must develop a device that can deliver drug eVectively to the lungs and, secondly, to produce devices that all patients can and will use eVectively. The pMDI and many other technologies can generate aerosols that will deliver drug to the lungs but there has been little eVort to meet the second objective. pMDIs are simple to use but very diYcult to use eVectively. It is inevitable that novel devices will come to the market in coming years, not least because of expiry of drug patents. However, to ensure that all patients derive maximum benefit from this form of therapy in the future it is important to understand the limitation of current delivery systems and to place patient issues squarely at the forefront of future developments. There is now a vast range of novel and impressive technologies available, but unfortunately aerosol scientists appear all too often to be caught up in this exciting technology, forgetting that devices are only there to serve the consumer. The technology is not an end in itself but a means to an end.
The article deliberately avoided proposing specific solutions as the pharmaceutical companies do face many challenges. A major problem is that we do not have a simple method of assessing the "therapeutic index" of a given device so it is very diYcult to determine whether a novel device and/or drug is "as safe" as others on the market; the principle of using the "lowest eVective dose" therefore remains the best guide. Consideration of the issues of compliance, competence and contrivance are, however, essential if future devices are to meet the needs of patients. The studies Professor Morice cites are certainly a move in the right direction since they attempt to address the relative benefits of drug/device combinations in the real world.
Professor Woodcock was indeed correct to note that it will be at least a year before inhaled insulin is used in clinical practice. This error was noted soon after the article went to press and a correction to this eVect appeared on the Thorax website before the article appeared in print and on page 978 of the November 2000 issue of Thorax. 1 He is, however, incorrect in both his estimation of the complexity of the device and of its likely price; any increase in cost will not be attributable to the production of the device but the premium charged for a novel form of treatment. The issue was raised to illustrate the point that simple to use, eVective devices can be developed to serve specific functions.
My views on compliance are far from paternalistic. As noted in the article, noncompliance is common in all diseases and the factors contributing to it are complex. There are no easy solutions for an issue that is responsible for excess morbidity, mortality, and healthcare costs. However, modern technology can certainly impinge on this area since, as Professor Morice notes, it is possible not only to monitor whether a device is used but also to monitor whether the device is used correctly. Monitoring compliance is likely to be introduced in North America if managed care organisations find that they can reduce costs. I do not know if patients or doctors want such facilities in their delivery systems, but since it is now possible to monitor compliance in this way, a grown up, informed debate should be initiated. Certainly, objective compliance data can significantly improve the quality of a consultation by allowing the patient and professional to concentrate on the factors adversely aVecting compliance in an open and honest dialogue.
It is to be hoped that in the future novel devices will use appropriate technology to meet the needs of the patient rather than developing devices that force patients to adapt to the technology. 
M L EVERARD
Time to consign cromoglycate to history?
Sodium cromoglycate (SCG) has become a minority option for the treatment of childhood asthma, 1 and even positive trials show only marginally relevant diVerences in the outcomes measured. 2 It is therefore interesting to recall that in 1967 the majority of asthmatic subjects were exposed to cigarette smoke and many had deformed chests. Children were not allowed to self-medicate or to receive their treatment at ordinary schools; the most aVected were sent to special schools and camps. Oral ephedrine and short acting theophylline preparations were standard treatment, but their eVectiveness was limited by tachyphylaxis.
The children who were treated with SCG when it was introduced experienced less the currently available alternative-dry powder inhalers-are perceived to be more costly. exercise induced asthma and were able to participate in playground games, often for the first time. In addition, fewer colds resulted in wheezing and exacerbations were shorter. The parents and physicians of these children were delighted with this safe remedy which was eVective for all but the most severe forms of the condition. The most popular formulation was a mixture of SCG with isoprenaline (Intal compound). This combined the immediate bronchodilator eVect of a rapidly acting adrenergic drug of extremely short duration with protection from antigen challenges and exercise induced asthma which lasted for about 6 hours.
Salbutamol was introduced in 1969, only 2 years after SCG, and had the same eVect in providing both relief and protection. As soon as salbutamol, permitted 6-hourly, became the rescue bronchodilator of choice, it became diYcult to demonstrate any clinically relevant benefit attributable solely to SCG in patients who were not dependent on oral steroids. Inhaled beclomethasone was introduced soon afterwards and this enabled even more asthmatics who were dependent on oral steroids to discontinue them. Beclomethasone does not have the unpleasant taste that makes SCG disagreeable to use, and suppresses more components of inflammation than SCG. Furthermore, beclomethasone rapidly reduces symptoms more eVectively for the same eVect on daytime FEV 1 and morning peak flow, possibly by reducing the sensation of inflammation in the airways. 3 By the time it was recognised that long term administration of higher doses of inhaled steroids produced significant side eVects in children and adults, long acting bronchodilators had been developed and proved to be useful in combination with medium doses of inhaled steroids. The possible use of cromoglycate, with its proven safety record, was not investigated in this context. There are no long term studies which show whether SCG played any part in the improved outcomes in childhood asthma between 1970 and 1980, or whether these are entirely the consequence of inhaled steroid use.
In a lucid contemporary account, one of the first investigators to test SCG described how he and his colleagues were disappointed to be unable to show any major eVect of SCG on FEV 1 in spite of a dramatic symptomatic and steroid sparing eVect. 4 At this time asthma was defined as variable or reversible airflow obstruction, and it was recognised that patients would judge the control of their condition by the frequency of regular, unexpected, or nocturnal attacks rather than by their best lung function. The value of frequent observation during the day was demonstrated by Chai et al 5 in 1968 and accepted in the late 1970s even by physicians who had previously regarded paroxysmal nocturnal dyspnoea as synonymous with pulmonary oedema. Helms 1 points out that regulators and authors of meta-analyses have a duty to examine appropriate outcomes. To promote informed discussion, they also need to be aware of the changing therapeutic options that were available when the studies under scrutiny were carried out. AUTHORS' REPLY Lazlo provides an historical perspective on the passing cromoglycate era in which he describes the dire state of asthma management, particularly in children, at the time that sodium cromoglycate (SCG) was introduced. He also points out that, soon after SCG was introduced, inhaled isoprenaline became available followed by the selective 2 agonist salbutamol. Although isoprenaline in combination with SCG was common in adult practice, it was used much less frequently in children. There are a number of other child/adult diVerences in practice and eVectiveness that underline the insecurities of extrapolation and inference. 1 The protective eVects of cromones on exercise induced bronchoconstriction are established, but are of relatively short duration 2 and are therefore unlikely to provide reliable and sustained protection against this troublesome symptom in active children. Whereas long acting agonists have proved to be useful in combination with moderate doses of inhaled steroids in adults, 3 the eVects in young children have been disappointing 4 and have been the subject of a narrative review. 5 Extrapolation of experience from predominantly adult studies into the paediatric age range has been a feature of asthma management but is increasingly being shown to be insecure, again emphasising the need for studies in children, particularly in those in younger age groups where the disease is most prevalent.
1 There is at least one long term study which attempted to assess the eVectiveness of SCG and which concluded that 60-70% of children with persistent symptoms improved over a 3-5 year period. 6 However, this study, which was an open extension to a formal double blind placebo controlled trial, could not take into account the natural rates of resolution and recurrence of the disease over this prolonged period. 7 Despite the popularity of SCG in the 1970s and early 1980s, it could be argued that its marginal eVectiveness, masked by its combined use with eVective bronchodilator agents, together with concerns about possible systemic eVects of steroids prolonged its appearance in the therapeutic armamentarium. The passing cromoglycate era certainly contains many lessons for the prescribing community, and among these must be an awareness of the natural history of the disease in childhood and the potential pitfalls of extrapolating lessons learnt in more severely aVected and older age groups into younger age groups.
